Login to Your Account



NewCo News: DLVR Hopes to 'Deliver' on siRNA Potential in Cancer

By Marie Powers


Monday, July 11, 2011
A bevy of U.S.-based firms – notably Alnylam Pharmaceuticals Inc., of Cambridge, Mass. – together with London-based Silence Therapeutics plc and, more recently, South Korean start-up BioMolecular Therapeutics, have been striving mightily to become first to market using RNAi-based platform technology to treat cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription